Drug Discovery Innovation Programme (DDIP)’s Post

While reaction miniaturization is a common practice in large pharmaceutical environments, understanding the associated risks and considerations for generating high-quality data in the context of assay miniaturization can be challenging. Read more about the I.DOT here and book a live demo today: https://lnkd.in/dCPvX9tg #IDOT #Technology #Automation #LifeSciences #LiquidHandling #LabAutomation #Development #DrugDiscovery #Genomics #SyntheticBiology #LaboratoryAutomation #FutureOfHealth

While reaction miniaturization is a common practice in large pharmaceutical environments, understanding the associated risks and considerations for generating high-quality data in the context of assay miniaturization can be challenging. Read more about the I.DOT here and book a live demo today: https://lnkd.in/dCPvX9tg #IDOT #Technology #Automation #LifeSciences #LiquidHandling #LabAutomation #Development #DrugDiscovery #Genomics #SyntheticBiology #LaboratoryAutomation #FutureOfHealth

Insightful video from AstraZeneca's Centre for Genomics Research. Here, Slavé Petrovski, VP, explains why AstraZeneca joined the Alliance for Genomic Discovery, alongside NashBio, Illumina, and 7 other pharma genomics pioneers. Their goal? To analyse 2 million genomes with a view to achieving 4 key objectives; - deliver novel insights into the biology of diseases; - enable the identification of new targets for medicines; - support selection of patients for clinical trials; - allow patients to be matched with treatments more likely to benefit them. Stay tuned for more updates on this ambitious initiative! The AGD Partners to date: Amgen AbbVie AstraZeneca Bayer Bristol Myers Squibb Merck MSD GSK Novo Nordisk NashBioIllumina #diseaseunderstanding #genomics #precisionmedicine #clinicaltrials #drugdiscovery

"Biology became a data science in the early 2000s, with the advent of genomic sequencing. In the coming years, we will witness another transformative shift as pharmaceutical companies target more rare diseases, stratify clinical trial subpopulations using biomarker and genetic data, and rely on more structured and unstructured patient data from a myriad of sources. Tools that help clinical study teams organize and interpret this deluge of data will be critical, as will a source of truth to use as a benchmark." – Genomenon Founder and CSO, Mark J. Kiel MD PhD and others share predictions for 2024. Read more via Clinical Research News: https://lnkd.in/d2GFrEZS

Best Selling Technologies for #Research, #Diagnostics and #Drugdevelopment 🧪🔬🦠🧑🔬 Whether you work as a researcher in a university lab, diagnose cancer and other #diseases in an NHS screening lab or develop new #drugs and #therapies in a private lab, you will want to know about these technologies 🔗 https://lnkd.in/eEA2gSPz #drugdiscovery #bioscience #biotech #biopharma #biologistics #lifesciences #diagnosticresearch #cells #cellmedia #antibody #antibodies #assays #cellassays #proteins #microbiology #molecularbiology #PCR #purification

🧬 Friday Morning Highlight! Genome Medical's innovative approach to #genetics care extends beyond just providing access to genetic services. The company also collaborates with health systems, molecular testing laboratories, and life sciences organizations to expand the practice and impact of genomic medicine. By partnering with biopharmaceutical organizations, Genome Medical helps accelerate the design, development, and launch of life-enhancing therapeutics. Through these partnerships, Genome Medical is able to leverage its expertise in genetics to support the development of new treatments and therapies. To learn more about Genome Medical's work with #biopharmaceutical companies and how they are leveraging clinical-grade data to boost #genomics, check out their story here: https://lnkd.in/gAfCeV2D.

"Oligos, Oligos, Oligos!" Coming Soon 🧬 3 Special Episodes from Waters and Friends Never have I been so privileged to assemble this many breakthroughs in science. Never have I used so many exclamation marks, either. I’m too excited. Hooray for #oligonucleotide-based medicine and the analytical science that supports these new drugs!❣ 📝 Register here: https://lnkd.in/e2CCvDgV Nov 7th: High-Throughput Oligo LC  Nov 14th: Improving and Simplifying Oligo PKPD Nov 21st: Deformulating & Analyzing CRISPR LNPs Congrats on your fantastic work Rachel Ginther, Samantha Sarni and Razvan Cojocaru. Your programs at MRIGlobal, Regeneron, and Acuitas Therapeutics, Inc. are so inspiring. Kudos to you too Szabolcs, Mary, and Mateusz for your hard work to advance methods for the quantitation and characterization of oligos. ------------------------------------ Oligonucleotide therapeutics and reagents are everywhere. They are helping the world address previously untreatable diseases, and they are also being used in new ways to sensitively quantify and sequence important translational research samples. Whether it be a CRISPR guide RNA, lipid conjugated anti-sense oligonucleotide, or a specially modified assay probe, these molecules must be tested to ensure they have the right sequence, pinpoint-specific modifications, conjugate moieties and purities. And when dosed as a therapeutic, they need to be carefully quantified to confirm pharmacokinetic models. Join the Waters chromatography and LC-MS team and their collaborators from MRIGlobal, Regeneron, and Acuitas Therapeutics in this special episodic, 3 week webinar series to learn more about the science of oligos and the power of LC-based approaches to analyze them. ---------------------------------------- #biotech #analyticalchemistry #HPLC #LCMS #genetherapy #celltherapy #CMC #PKPD #ADME #LifeatWaters Waters Corporation

Webinar Alert! 🚨 Excited to share that I'll be presenting my latest research on developing #lcms methods for bioanalysis of chemically modified #siRNAs at the upcoming webinar series hosted by @WatersCorp! 🧪🧬 Join me as I delve into the challenges and breakthroughs in this field. Don't miss this opportunity to learn from industry experts and expand your knowledge. 💡 Register using the link from Matt's post.

In the ever-evolving landscape of drug discovery, innovative technologies continually emerge to address complex challenges. Among these, 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬9 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐬𝐭𝐚𝐧𝐝𝐬 𝐨𝐮𝐭 𝐚𝐬 𝐚 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐭𝐨𝐨𝐥 with profound implications for drug discovery research. By allowing precise genome editing in a variety of organisms, CRISPR has unlocked new avenues for understanding disease mechanisms, identifying therapeutic targets, and developing novel treatments. 𝐑𝐞𝐚𝐝 𝐅𝐮𝐥𝐥 𝐁𝐥𝐨𝐠:https://bit.ly/3Q5Sjbw 𝐄𝐦𝐚𝐢𝐥 𝐮𝐬 𝐚𝐭 : info@worldbigroup.com #drugdiscovery #innovation #genomics #sciencestudent #steam #scientist #phdresearch #biologics #medicinalchem #drugdiscovery #oncology #bioinformatics #genomics #medicinalchemistry #licensing #drugdiscoveryconference2024 #ddip24

📢 Call to all scientists working with oligos 📢 Don't miss these 3 special episodes focusing on the analysis of #oligonucleotide-based drugs. Particularly interesting for #bioanalysts will be the second one, in which we will hear from our guest speaker Samantha Sarni from Regeneron and our expert Mary Trudeau, on how they overcome their challenges in oligo PKPD working with the #OligoWorks kit. Register here 👇 https://lnkd.in/eYkDf6eT #oligonucleotides #PKPD #ADME #bioanalysis #OligoWorks #Waters